News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Nomura: TIGERMED (03347.HK) Directors and Controlling Shareholders Placed Under Investigation, Expects Short-term Share Price Pressure
Nomura published a report stating that on May 12 (yesterday) evening, TIGERMED (03347.HK) announced that director and controlling shareholder Ye Xiaoping and Cao Xiaochun have rece...
Reset
Send
The window will close in 5 seconds
Nomura: TIGERMED (03347.HK) Directors and Controlling Shareholders Placed Under Investigation, Expects Short-term Share Price Pressure
Close
Recommend
5
Positive
1
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Nomura published a report stating that on May 12 (yesterday) evening, TIGERMED (03347.HK)  -0.360 (-1.111%)    Short selling $4.02M; Ratio 6.553%   announced that director and controlling shareholder Ye Xiaoping and Cao Xiaochun have received a notice of investigation from the China Securities Regulatory Commission for alleged violations of laws and regulations in information disclosure related to changes in the companys equity interests.

Nomura noted that specific details of the investigation are still pending. It believes the probe is likely related to the two individuals past share placements and whether such transactions were compliant. Notably, the companys Chinese announcement emphasized that the two controlling shareholders had made public announcements and disclosures in accordance with regulations for each share placement, while the English announcement did not mention this point.

Related NewsTIGERMED (03347.HK) Falls 3% by Midday to Near One-Year Low After JPM Cuts TP to HKD39
The broker said it is currently unable to quantify the potential legal consequences the two controlling shareholders may face, which could include fines. Regardless of the final outcome, the share price is expected to face downward pressure in the short term.

Nomura maintained a Neutral rating on TIGERMED with a TP of HKD28.56. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.